Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic atrophy linked to AMD. Alkeus Pharmaceuticals, Inc., announced additional ...

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

According to Dr. Danzig, the DIAMOND trial demonstrates efficacy of OCS-01, a topical drop, in patients with diabetic macular edema. Carl Danzig, MD, director of vitreo-retinal services at the Rand ...

The phase 2 clinical trial data evaluating the efficacy, safety, and dosing intervals of high-dose IBI302 were presented during the annual 2025 ARVO meeting. Innovent Biologics recently announced its ...

The Retinal Genix plans to use the facility to further the development of its DNA/RNA/GPS Pharmaco-Genetic Mapping platform. RetinalGenix has signed a new laboratory lease agreement with life science ...

Jennifer Lim, MD, FARVO, FASRS, discusses her ARVO presentation on sickle cell retinopathy, highlighting improvements in retinal surgery techniques and instrumentation. Joining the Eye Care Network in ...

Preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) was recently announced by ANI Pharmaceuticals. 1 Cotrophin Gel is a prescription injection indicated for ...

Dosing our first patient in the VAN-2401 phase 1 trial is an important milestone in the advancement of KH658 by exploring the ...

KIO-104 is a therapeutic candidate shown to significantly reduce retinal scar formation. KIO-104, a small molecular DHODH inhibitor, works by suppressing T cell replication and function. The ...